arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Rezolute, Inc.

RZLT Health Care Biotechnology: Pharmaceutical Preparations
$4.68
Today
as of Aug 5, 16:53 ET
Last 30 days -8.24% Jun 29 → Aug 05
$4.29 $4.57 $4.84 $5.11 $5.39 Jun 29 Jul 07 Jul 14 Jul 22 Jul 29 Aug 05
Open
$4.52
High
$4.63
Low
$4.18
Volume
$2M
Avg Vol
$3M
Mkt Cap
$315M
P/E (TTM)
—
Beta
—
52w High
$11.46
52w Low
$1.07
Div Yield
—
Shares Out
$96M

Recent Press Releases & News last 60 days · 3 items

Jul 21 · 11:30 PR GlobeNewswire
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Jun 17 · 11:00 PR GlobeNewswire
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Jun 10 · 11:46 Simply Wall St.
Positive Signs As Multiple Insiders Buy Rezolute Stock

Overview

52-week range
$1.07
$11
35% of range
Avg surprise (last 2)
-22.9%
Avg reaction (last 2)
+1.2%
50% positive
Latest IV / EM
109%
EM ±18.2% · $5 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.34$-0.29$-0.24$-0.18$-0.13 Actual $-0.28Actual $-0.27Actual $-0.34Actual $-0.22Actual $-0.22Actual $-0.27Est $-0.22Actual $-0.18Actual $-0.22Actual $-0.16Est $-0.13 SepDecMarSepDecMar/2025SepDecMar/2026
Revenue vs Net Income Revenue Net income
$-23M$-21M$-19M$-18M$-16M Sep 24Dec 24Mar 25Sep 25Dec 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 12, 2026Mar/2026 $-0.16 $-0.13 -23.1% +40.7% +4.1% earnings
Wed Dec 31, 2025Dec 2025 $-0.22 — — — — financials
Tue Sep 30, 2025Sep 2025 $-0.18 — — — — financials
Tue May 13, 2025Mar/2025 $-0.27 $-0.22 -22.7% — -1.6% earnings
Tue Dec 31, 2024Dec 2024 $-0.22 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.22 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.34 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.27 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.28 — — — — financials

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-17M$-24M$-20M—$-20M$-17M$-17M—
Net income$-16M$-23M$-18M—$-19M$-16M$-15M—
EPS (diluted)$-0.16$-0.22$-0.18—$-0.27$-0.22$-0.22—

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$11M$12M$9M$94M$15M$9M$10M$70M
Inventory————————
Total current assets$122M$135M$155M$171M$89M$99M$110M$129M
Total assets$125M$139M$159M$175M$95M$112M$123M$133M
Long-term debt————————
Total liabilities$9M$11M$11M$13M$12M$12M$10M$12M
Total equity$117M$128M$147M$162M$83M$100M$113M$121M

Implied volatility — last 90 days

68%229%390%551%712% Jun 08 — IV 232% · EM ±30.6%Jun 09 — IV 633% · EM ±79.3%Jun 10 — IV 554% · EM ±65.4%Jun 11 — IV 611% · EM ±67.5%Jun 12 — IV 611% · EM ±62.5%Jun 15 — IV 350% · EM ±25.3%Jun 16 — IV 253% · EM ±15.0%Jun 17 — IV 335% · EM ±14.0%Jun 19 — IV 142% · EM ±31.4%Jun 22 — IV 98% · EM ±20.4%Jun 23 — IV 85% · EM ±17.4%Jun 24 — IV 99% · EM ±19.8%Jun 26 — IV 98% · EM ±18.8%Jun 29 — IV 108% · EM ±19.1%Jun 30 — IV 107% · EM ±18.3%Jul 01 — IV 109% · EM ±18.2%Jul 02 — IV 176% · EM ±28.5%Jul 03 — IV 179% · EM ±28.0%Jul 06 — IV 113% · EM ±15.7%Jul 07 — IV 132% · EM ±17.4%Jul 08 — IV 185% · EM ±23.2%Jul 09 — IV 107% · EM ±12.7%Jul 10 — IV 176% · EM ±19.5%Jul 13 — IV 139% · EM ±11.6%Jul 14 — IV 658% · EM ±47.6%Jul 15 — IV 196% · EM ±11.6%Jul 16 — IV 712% · EM ±29.7%Jul 20 — IV 117% · EM ±27.5%Jul 21 — IV 109% · EM ±25.4%Jul 22 — IV 109% · EM ±25.0%Jul 23 — IV 122% · EM ±27.4%Jul 24 — IV 113% · EM ±25.1%Jul 27 — IV 87% · EM ±18.2%Jul 28 — IV 107% · EM ±21.9%Jul 29 — IV 96% · EM ±19.2%Jul 30 — IV 68% · EM ±13.3%Jul 31 — IV 161% · EM ±30.7%Aug 03 — IV 86% · EM ±15.2%Aug 04 — IV 140% · EM ±24.2%Aug 05 — IV 109% · EM ±18.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,164.75-0.4%
JNJ
Johnson & Johnson
$624.1B $258.23+0.2%
ABBV
AbbVie Inc.
$454.8B $246.35+0.1%
MRK
Merck & Company, Inc.
$321.6B $129.20+0.7%
PM
Philip Morris International Inc
$299.3B $188.93-0.0%
NVS
Novartis AG
$297.9B $154.440.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in